Amarin Pharma Inc.
Third floor,Mystic Packer Building
12 Roosevelt Ave.
Mystic
CT
06355
USA
(866) 960-7367
(860) 572-4940
http://www.amarincorp.com
Product Categories
Pharmaceuticals

Related Content

Amarin Corporation plc announced that research on the potential population health impact and cost-effectiveness of VASCEPA (icosapent ethyl), presented in two poster presentations at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022
News | Pharmaceuticals
Research Presented at AHA's QCOR Scientific Sessions Indicate Potential for Vascepa to Reduce Major Adverse CV Events

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 24, 2022
arrow
Research Presented at the American Heart Association’s Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs
News | Pharmaceuticals
Research Shows Potential to Reduce Major Cardiovascular (CV) Events

May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 17, 2022
arrow
Vascepa
News | Stroke
JAHA Study: Vascepa Significantly Lowered Risk of Potentially Fatal CVD Events in Patients with Prior PCI

March 15, 2022 – Amarin has announced the publication of new REDUCE-IT data analysis that helps support the clinical ...

Home March 11, 2022
arrow
Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque (LAP) volume on multidetector computed tomography (MDCT) compared with placebo over 18 months in the EVAPORATE Trial
News | Pharmaceuticals
Icosapent Ethyl Significantly Reduces Coronary Plaque in EVAPORATE Study

September 10, 2020 - Icosapent ethyl (Vascepa) demonstrated significant, 17 percent regression of low attenuation plaque ...

Home September 10, 2020
arrow
Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals| Dave Fornell, Editor
FDA Expands Vascepa to Reduce Cardiovascular Events in Elevated Triglyceride Patients

December 16, 2019 — The U.S. Food and Drug Administration (FDA), on Dec. 13, approved the use of Vascepa (icosapent ...

Home December 16, 2019
arrow
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals
FDA Grants Priority Review for Vascepa sNDA

May 29, 2019 — Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl ...

Home May 29, 2019
arrow
News
Drug Tested to Lower Triglycerides in At-Risk Patients

January 11, 2010 – The first patients were enrolled in the phase 3 clinical trials for a drug designed to lower ...

Home January 11, 2010
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now